• Je něco špatně v tomto záznamu ?

Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review

K. Mori, N. Miura, M. Babjuk, PI. Karakiewicz, H. Mostafaei, E. Laukhtina, F. Quhal, RS. Motlagh, B. Pradere, S. Kimura, S. Egawa, SF. Shariat

. 2020 ; 38 (10) : 774-782. [pub] 20200710

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020094

PURPOSE: This systematic review assessed compliance to guidelines for the management of nonmuscle-invasive bladder carcinoma (NMIBC). METHODS: The PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in November 2019 in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis statement. RESULTS: Fifteen studies incorporating a collective total of 10,575 NMIBC patients were eligible for inclusion in this systematic review. We found that the rates of compliance were 53.0% with a single immediate intravesical instillation in patients with presumed low or intermediate risk, 37.1% with intravesical bacillus Calmette-Guerin or chemotherapy in those with intermediate risk, 43.4% with performance of a second transurethral resection in high-risk patients, 32.5% with administration of adjuvant intravesical bacillus Calmette-Guerin in high-risk patients, 36.1% with radical cystectomy in highest-risk patients, and 82.2% with cystoscopy for follow-up. CONCLUSIONS: Compliance with NMIBC guidelines remains low. Better guideline education and understanding holds the key to achieving high compliance. Strategies to improve guideline compliance at the physician level are urgently required.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020094
003      
CZ-PrNML
005      
20210830101712.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urolonc.2020.06.013 $2 doi
035    __
$a (PubMed)32654948
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
245    10
$a Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review / $c K. Mori, N. Miura, M. Babjuk, PI. Karakiewicz, H. Mostafaei, E. Laukhtina, F. Quhal, RS. Motlagh, B. Pradere, S. Kimura, S. Egawa, SF. Shariat
520    9_
$a PURPOSE: This systematic review assessed compliance to guidelines for the management of nonmuscle-invasive bladder carcinoma (NMIBC). METHODS: The PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in November 2019 in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis statement. RESULTS: Fifteen studies incorporating a collective total of 10,575 NMIBC patients were eligible for inclusion in this systematic review. We found that the rates of compliance were 53.0% with a single immediate intravesical instillation in patients with presumed low or intermediate risk, 37.1% with intravesical bacillus Calmette-Guerin or chemotherapy in those with intermediate risk, 43.4% with performance of a second transurethral resection in high-risk patients, 32.5% with administration of adjuvant intravesical bacillus Calmette-Guerin in high-risk patients, 36.1% with radical cystectomy in highest-risk patients, and 82.2% with cystoscopy for follow-up. CONCLUSIONS: Compliance with NMIBC guidelines remains low. Better guideline education and understanding holds the key to achieving high compliance. Strategies to improve guideline compliance at the physician level are urgently required.
650    _2
$a adjuvancia imunologická $x aplikace a dávkování $7 D000276
650    _2
$a aplikace intravezikální $7 D000283
650    _2
$a následná péče $x normy $x statistika a číselné údaje $7 D000359
650    _2
$a protinádorové látky $x aplikace a dávkování $7 D000970
650    _2
$a BCG vakcína $x aplikace a dávkování $7 D001500
650    _2
$a karcinom z přechodných buněk $x diagnóza $x patologie $x terapie $7 D002295
650    _2
$a adjuvantní chemoterapie $x metody $x normy $x statistika a číselné údaje $7 D017024
650    _2
$a cystektomie $x normy $x statistika a číselné údaje $7 D015653
650    _2
$a cystoskopie $x normy $x statistika a číselné údaje $7 D003558
650    _2
$a dodržování směrnic $x statistika a číselné údaje $7 D019983
650    _2
$a lidé $7 D006801
650    _2
$a lékařská onkologie $x normy $x statistika a číselné údaje $7 D008495
650    _2
$a hladké svalstvo $x diagnostické zobrazování $x patologie $x chirurgie $7 D009130
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a močový měchýř $x diagnostické zobrazování $x patologie $x chirurgie $7 D001743
650    _2
$a nádory močového měchýře $x diagnóza $x patologie $x terapie $7 D001749
650    _2
$a urologie $x normy $x statistika a číselné údaje $7 D014572
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Miura, Noriyoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
700    1_
$a Babjuk, Marek $u Department of Urology, Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Motlagh, Reza Sari $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, CHRU Tours, Francois Rabelais University, France
700    1_
$a Kimura, Shoji $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Jordan, Amman, Jordan; European Association of Urology Research Foundation, Arnhem, the Netherlands. Electronic address: shahrokh.shariat@meduriwien.ac.at
773    0_
$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 38, č. 10 (2020), s. 774-782
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32654948 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101712 $b ABA008
999    __
$a ok $b bmc $g 1690811 $s 1140540
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 10 $d 774-782 $e 20200710 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace